Skip to content
Nikang Therapeutics
About Us
Science & Pipeline
News
Careers
Home
About us
Science & Pipeline
News
Careers
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets